Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript
Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 10,989,282 | $302,315,161 | -4% | 2.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | Officer | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | Officer | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | Director | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | Director | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | Large Shareholder | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.99 | 2,297 | 81,571 | 2024-03-04 | Filing | ||
| $32.99 | 605 | 71,470 | 2024-03-04 | Filing | ||
| $29.38 | 667 | 43,927 | 2024-01-08 | Filing | ||
| $28.66 | 1,608 | 44,594 | 2024-01-08 | Filing | ||
| $29.46 | 19,223 | 846,486 | 2024-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,010,695 | $274,736,101 | 0% | |
| 2. | 8,347,449 | $254,513,720 | 0% | |
| 3. | 4,735,861 | $144,396,402 | 0% | |
| 4. | 3,478,562 | $106,061,355 | 0.07% | |
| 5. | 3,478,562 | $105,956,999 | 1.01% |
News See All
Top 11 CRISPR Stocks To Invest In
Genome editing refers to a set of technologies enabling scientists to modify an organism's DNA by adding, removing, or altering genetic material at specific locations in the genome, as defined by MedlinePlus...
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
5 Best Genomics Stocks To Buy Now
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a gene editing company developing treatments for cancer and immune system diseases.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Wood's Portfolio
In this article, we will take a look at the 16 best stocks to buy and hold for the next 15 years according to Cathie Wood's portfolio.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Intellia Therapeutics' Second Quarter 2023 Earnings Conference Call. My name is Drew and I will be your conference operator today.
10 DNA Stocks Billionaires Are Loading Up On
Genomics is the study of a complete set of DNA within an organism.
Billionaire Hedge Funds
